<DOC>
	<DOCNO>NCT01027377</DOCNO>
	<brief_summary>The study investigate safety , tolerability , pharmacokinetics ( determination concentration administer drug blood time ) recombinant Factor VIII Fc fusion protein ( rFVIIIFc ) previously-treated subject severe hemophilia A .</brief_summary>
	<brief_title>Study Recombinant Factor VIII Fc Fusion Protein ( rFVIIIFc ) Subjects With Severe Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>1 . Male 12 year age old weigh least 40 kg 2 . Diagnosed severe hemophilia A ( baseline Factor VIII level le 1 % ) 3 . History least 100 exposure day Factor VIII product 1 . History Factor VIII inhibitor 2 . Kidney liver dysfunction 3 . Diagnosed another coagulation defect hemophilia A</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>